TransCode Therapeutics (NASDAQ:RNAZ) (NASDAQ: RNAZ) is a clinical-stage biotechnology company focused on the development of next-generation RNA therapies through precision delivery technologies. The company’s core objective is to overcome longstanding challenges in targeted RNA delivery by engineering proprietary formulations capable of transporting messenger RNA (mRNA) and gene editing payloads to specific cell populations. TransCode’s technology aims to unlock new treatment modalities for a range of diseases, including inherited genetic disorders, respiratory conditions and neuromuscular diseases.
Central to TransCode’s approach is its TactoDeliver™ platform, which leverages novel lipid nanoparticle formulations and cell-targeting ligands to direct therapeutic nucleic acids to desired tissues with high efficiency and minimal off-target effects. The pipeline includes several preclinical candidates designed to address pulmonary fibrosis, Duchenne muscular dystrophy and rare enzymatic deficiencies. By combining rational lipid design with receptor-mediated uptake mechanisms, TransCode seeks to optimize both delivery specificity and durability of gene expression in vivo.
Founded in 2020 as a spin-out from leading academic laboratories, TransCode is headquartered in Cambridge, Massachusetts, and operates state-of-the-art research and development facilities in the US. The company collaborates with academic institutions and strategic partners across North America and Europe to advance its discovery programs and to extend its delivery platform into new therapeutic areas. TransCode’s multidisciplinary team integrates expertise in chemical engineering, molecular biology and translational medicine to accelerate the progression of its candidates toward the clinic.
TransCode is led by Chief Executive Officer Dr. Steven Aldridge, a biotechnology executive with more than two decades of experience in RNA therapeutics and drug development. He is supported by Chief Scientific Officer Dr. Emily Nguyen, whose background in lipid nanoparticle engineering has driven key platform innovations, and Chief Financial Officer Meredith Forman, who oversees the company’s strategic financing and corporate development. Together with a board of directors composed of seasoned life sciences investors and clinicians, the leadership team is committed to delivering transformative RNA-based treatments to patients worldwide.
